Epigenomics AG
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The co…
Medical - Diagnostics & Research
DE, Berlin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 9.03 | 9.03 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 11.28 | 4.25 | 3.82 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | -9.39 | -9.39 | |
| Cash | 0.00 | 2.47 | 2.47 | |
| Capex | 0.00 | < 0.005 | < 0.005 | |
| Free Cash Flow | 0.00 | 0.44 | 0.44 | |
| Revenue | 0.00 | 0.08 | 0.08 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | 0.90 | 0.90 | |
| Operating Margin | 0.00 | 31.77 | 31.77 | |
| ROA | 0.00 | 0.15 | 0.15 | |
| ROE | 0.00 | -0.23 | -0.23 | |
| ROIC | 0.00 | 0.56 | 0.56 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of EPGNF is permitted for members.
5
Growth
The "Growth Entry" for the Focus of EPGNF is permitted for members.
6
Leverage & Liquidity